ClearPath Diagnostics is First in Upstate New York with Cervista™ HPV HR: Advanced High-Risk HPV Screening - Important Tool in Assessment of Cervical Cancer Risk

Share Article

ClearPath Diagnostics to perform Cervista™ HPV HR test to screen for the presence of high risk types of the human papillomavirous, which is strongly associated with the development of cervical cancer.

ClearPath Diagnostics, a physician-owned pathology and cytology laboratory located in Syracuse, NY, is the first laboratory in upstate New York to perform the Cervista™ HPV HR test to screen for the presence of high-risk types of the human papillomavirous, which is strongly associated with the development of cervical cancer.

FDA-approved Cervista HPV HR is the first new screening test for high-risk HPV in more than a decade. It provides more reliable test results along with important laboratory efficiencies.

According to the National Cancer Institute, approximately 11,000 women in the United States are diagnosed with cervical cancer each year and about 4,000 die of the disease. Cervical cancer is highly treatable in most cases if detected early.

The Cervista HPV HR test is used in combination with Pap testing, sharing the same cervical specimen. Cervista additionally performs genotyping testing on the same Pap specimen to more specifically determine if the patient is positive for certain high-risk cell variations, which, when combined, are the cause of 70 percent of cervical cancer cases. Cervista HPV HR detects the presence of 14 high-risk HPV types.

Studies have noted that women with high-risk HPV infections are at greater risk of developing cervical cancer and its precursor conditions in the future. “Just as the ThinPrep Pap was an improvement over the conventional Pap, Cervista is an improvement on prior methods of HPV testing,” Michael Mazur, M.D., ClearPath Diagnostics lab director, said.

“ClearPath Diagnostics” is committed to providing our patients with the leading technology to detect disease early,” said Michael A. Jozefczyk, M.D., president, ClearPath Diagnostics. “With Cervista HPV HR, we can confidently provide more accurate test results on half the patient sample size. Cervista is the first high risk HPV assay that includes a quality control check, which will greatly reduce the number of false positive results.”

ClearPath Diagnostics (http://www.clearpathdiagnostics.com), is a physician-owned pathology and cytopathology laboratory with representatives in Syracuse, NY, Binghamton, NY, Albany, NY, Utica, NY and Scranton, PA. For more information, call 315-234-3300 or email info(at)clearpathdiagnostics(dot)com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Stewart Koenig
KOENIG ADVERTISING PUBLIC RELATIONS
(315) 475-1603
Email >
Visit website